Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
Repare Therapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/repare-therapeutics” connections=”true” suffix=””]
In Jan 2019, Repare Therapeutics, Inc. Enters into Strategic Partnership Agreement With ONO Pharmaceutical Co., Ltd. for Repare’s Polθ Inhibitor Program. Under the terms of the agreement, ONO will provide an up-front payment and research service payments potentially totaling US $15M, plus additional cost-sharing through IND..